Africa to get BioNTech mRNA vaccine factory soon
BioNTech has said the BioNTainers could make other mRNA vaccines against malaria or tuberculosis, depending on product development progress and future public-health priorities.
Frankfurt: COVID-19 vaccine maker BioNTech said construction of an mRNA vaccine factory to enable African nations to jump-start their own manufacturing network would start on June 23 in Rwanda.The groundbreaking ceremony in the capital city of Kigali is to be attended by Rwanda's President Paul Kagame, further heads of African states, as well as representatives from the European Union and...
Login or Register to read the full article
Frankfurt: COVID-19 vaccine maker BioNTech said construction of an mRNA vaccine factory to enable African nations to jump-start their own manufacturing network would start on June 23 in Rwanda.
The groundbreaking ceremony in the capital city of Kigali is to be attended by Rwanda's President Paul Kagame, further heads of African states, as well as representatives from the European Union and the World Health Organization, the biotech firm said in a statement on Thursday.
The German company's modular factory elements, to be assembled in Africa to so-called BioNTainers, would be delivered to the Kigali construction site by the end of 2022, it added.
The company, which developed the western world's most widely used COVID-19 shot with U.S. partner Pfizer, earlier this year mapped out a plan to enable African countries to produce its Comirnaty-branded shot under BioNTech's supervision.
The company has said that the initial vaccine factory, made from an assembly kit and housed in shipping containers, would over the next few years become part of a wider supply network spanning several African nations including Senegal and South Africa.
The project push comes as Western-made coronavirus vaccine doses finally arrive in force on the continent, after a much criticised delay.
But uptake in Africa has fallen short of expectations, hurt by misinformation, logistical problems and a lacking sense of urgency in the population, among other factors.
BioNTech has said the BioNTainers could make other mRNA vaccines against malaria or tuberculosis, depending on product development progress and future public-health priorities.
Read also: Pfizer-BioNTech seeks USFDA authorisation for COVID vaccine for kids under 5 years
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd